A reported genetic association does not automatically provide a useful test for predicting an individual’s response to methamphetamine. Kalayasiri and colleagues’ 2014 Thai treatment-cohort study described a preliminary DBH association with methamphetamine-induced paranoia. The authors explicitly stated that the finding was not significant after correction for multiple testing.
What clinical outcome was studied?
The research included 727 people meeting methamphetamine-dependence criteria from a Thai rehabilitation setting during 2007–2011. Clinical histories were collected retrospectively with structured interviews, including the Methamphetamine Experience Questionnaire.
Paranoia was operationally defined as irrational distrust or fear of others without a realistic potential for harm. This was a specific reported phenotype, not a diagnosis of every form of psychosis. Of the 727 dependent participants, 289, approximately 40%, reported that phenotype.
That percentage belongs to a selected treatment cohort. Participants with histories of primary psychotic disorders or certain brain diseases were excluded. It cannot be treated as a community prevalence estimate or the probability that any person exposed to methamphetamine will become paranoid.
Why was the genetic sample smaller?
DNA was extracted from whole blood and the researchers examined the DBH −1021C→T variant, also identified as rs1611115. This blood procedure measured genetic material; it did not establish a methamphetamine concentration at the time of a paranoid episode.
Genetic data were unavailable for 55 clinical participants, and ancestry restrictions further limited the association analysis. The final genetic sample was 646, including 261 with paranoia and 385 without. Reusing 727 as the denominator for every genetic comparison would misdescribe the analysis.
What was the nominal finding?
The individual genotype comparisons did not establish a significant difference. Combining TT and CT carriers for an exploratory comparison with CC carriers produced a nominal association. After adjustment for selected clinical variables, the reported odds ratio was 0.7, with a 95% confidence interval of 0.5–0.98 and p=0.04.
The confidence interval approached the no-association value of one. More importantly, the investigators performed multiple statistical comparisons and stated that the genetic findings did not remain significant after correction. Describing the variant simply as a proven protective gene would omit that central limitation.
What additional uncertainties matter?
The candidate-gene approach selected one biologically plausible variant rather than establishing a comprehensive genetic model. Ancestry restrictions reduced some heterogeneity but did not substitute for genetic control of population structure. The authors identified residual population stratification as a major concern requiring replication.
Retrospective symptom and exposure histories were vulnerable to recall error. In a smaller reliability assessment of 79 participants, the paranoia classification had moderate inter-rater agreement. Imperfect outcome classification can affect an association even when laboratory genotyping is technically sound.
Does the study validate individual prediction?
No diagnostic sensitivity, specificity or independently validated individual prediction rule was established. An odds ratio describes a comparison between groups; it does not identify who will develop symptoms, determine the cause of a past episode or reconstruct someone’s mental state.
The authors also observed shorter recalled onset latency during later paranoid episodes without a corresponding significant change in reported intake. That observation was consistent with a sensitization hypothesis, but remained retrospective rather than an experimentally demonstrated mechanism.
The historical study supports further investigation of clinical and genetic heterogeneity. Its preliminary label, multiplicity limitation and need for ancestry-controlled replication should remain attached to any claim based on the DBH result.
Source
Kalayasiri R, Verachai V, Gelernter J, Mutirangura A, Malison RT. Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH −1021C→T in a Thai treatment cohort. Addiction. 2014;109(6):965–976. doi:10.1111/add.12512.
Leave a Reply